174 related articles for article (PubMed ID: 37460715)
1. FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway.
Chen G; Sun L; Gu X; Ai L; Yang J; Zhang Z; Hou P; Wang Y; Ou X; Jiang X; Qiao X; Ma Q; Niu N; Xue J; Zhang H; Yang Y; Liu C
Sci China Life Sci; 2023 Dec; 66(12):2805-2817. PubMed ID: 37460715
[TBL] [Abstract][Full Text] [Related]
2. FSIP1 regulates autophagy in breast cancer.
Liu C; Sun L; Yang J; Liu T; Yang Y; Kim SM; Ou X; Wang Y; Sun L; Zaidi M; New MI; Yuen T; Guo Q
Proc Natl Acad Sci U S A; 2018 Dec; 115(51):13075-13080. PubMed ID: 30509973
[TBL] [Abstract][Full Text] [Related]
3. 4-Acetylantroquinonol B induced DNA damage response signaling and apoptosis via suppressing CDK2/CDK4 expression in triple negative breast cancer cells.
Satriyo PB; Su CM; Ong JR; Huang WC; Fong IH; Lin CC; Aryandono T; Haryana SM; Deng L; Huang CC; Tzeng YM; Chao TY; Liu HW; Yeh CT
Toxicol Appl Pharmacol; 2021 Jul; 422():115493. PubMed ID: 33727089
[TBL] [Abstract][Full Text] [Related]
4. FSIP1 binds HER2 directly to regulate breast cancer growth and invasiveness.
Liu T; Zhang H; Sun L; Zhao D; Liu P; Yan M; Zaidi N; Izadmehr S; Gupta A; Abu-Amer W; Luo M; Yang J; Ou X; Wang Y; Bai X; Wang Y; New MI; Zaidi M; Yuen T; Liu C
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):7683-7688. PubMed ID: 28674022
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
Lee J; Lim B; Pearson T; Choi K; Fuson JA; Bartholomeusz C; Paradiso LJ; Myers T; Tripathy D; Ueno NT
Breast Cancer Res Treat; 2019 Jun; 175(2):339-351. PubMed ID: 30826934
[TBL] [Abstract][Full Text] [Related]
6. Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
Li T; Xiong Y; Wang Q; Chen F; Zeng Y; Yu X; Wang Y; Zhou F; Zhou Y
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4001-4011. PubMed ID: 31588803
[TBL] [Abstract][Full Text] [Related]
7. Over-expression of FSIP1 promotes breast cancer progression and confers resistance to docetaxel via MRP1 stabilization.
Yan M; Wang J; Ren Y; Li L; He W; Zhang Y; Liu T; Li Z
Cell Death Dis; 2019 Feb; 10(3):204. PubMed ID: 30814489
[TBL] [Abstract][Full Text] [Related]
8. Elevated fibrous sheath interacting protein 1 levels are associated with poor prognosis in non-small cell lung cancer patients.
Mao Y; Xu R; Liu X; Shi W; Han Y
Oncotarget; 2017 Feb; 8(7):12186-12193. PubMed ID: 28086239
[TBL] [Abstract][Full Text] [Related]
9. C9orf142 transcriptionally activates MTBP to drive progression and resistance to CDK4/6 inhibitor in triple-negative breast cancer.
Liao L; Deng L; Zhang YL; Yang SY; Andriani L; Hu SY; Zhang FL; Shao ZM; Li DQ
Clin Transl Med; 2023 Nov; 13(11):e1480. PubMed ID: 38009308
[TBL] [Abstract][Full Text] [Related]
10. RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypes.
Pesch AM; Hirsh NH; Michmerhuizen AR; Jungles KM; Wilder-Romans K; Chandler BC; Liu M; Lerner LM; Nino CA; Ward C; Cobain EF; Lawrence TS; Pierce LJ; Rae JM; Speers CW
JCI Insight; 2022 Feb; 7(3):. PubMed ID: 34932500
[TBL] [Abstract][Full Text] [Related]
11. FSIP1 is correlated with estrogen receptor status and poor prognosis.
Li X; Song X; Ma J; Zhao Y; Jiang Q; Zhao Z; Li M
Mol Carcinog; 2020 Jan; 59(1):126-135. PubMed ID: 31713931
[TBL] [Abstract][Full Text] [Related]
12. Clinical considerations of CDK4/6 inhibitors in triple-negative breast cancer.
Wang R; Xu K; Gao F; Huang J; Guan X
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188590. PubMed ID: 34271137
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer.
Peng WT; Jin X; Xu XE; Yang YS; Ma D; Shao ZM; Jiang YZ
Cancer Res; 2023 May; 83(10):1711-1724. PubMed ID: 37129951
[TBL] [Abstract][Full Text] [Related]
14. Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer.
Ge JY; Shu S; Kwon M; Jovanović B; Murphy K; Gulvady A; Fassl A; Trinh A; Kuang Y; Heavey GA; Luoma A; Paweletz C; Thorner AR; Wucherpfennig KW; Qi J; Brown M; Sicinski P; McDonald TO; Pellman D; Michor F; Polyak K
Nat Commun; 2020 May; 11(1):2350. PubMed ID: 32393766
[TBL] [Abstract][Full Text] [Related]
15. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer.
Zhu X; Chen L; Huang B; Li X; Yang L; Hu X; Jiang Y; Shao Z; Wang Z
J Exp Clin Cancer Res; 2021 Apr; 40(1):122. PubMed ID: 33832512
[TBL] [Abstract][Full Text] [Related]
17. Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer.
Teo ZL; Versaci S; Dushyanthen S; Caramia F; Savas P; Mintoff CP; Zethoven M; Virassamy B; Luen SJ; McArthur GA; Phillips WA; Darcy PK; Loi S
Cancer Res; 2017 Nov; 77(22):6340-6352. PubMed ID: 28947417
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer.
Chen X; Shu C; Li W; Hou Q; Luo G; Yang K; Wu X
J Med Chem; 2022 May; 65(9):6729-6747. PubMed ID: 35447031
[TBL] [Abstract][Full Text] [Related]
19. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy.
McClendon AK; Dean JL; Rivadeneira DB; Yu JE; Reed CA; Gao E; Farber JL; Force T; Koch WJ; Knudsen ES
Cell Cycle; 2012 Jul; 11(14):2747-55. PubMed ID: 22751436
[TBL] [Abstract][Full Text] [Related]
20. A novel ribociclib derivative WXJ-103 exerts anti-breast cancer effect through CDK4/6.
Ji J; Zhang Z; He X; Pan G; Li G; Lv J; Xu Y; Xie M; Feng J; Wang W; Liu B; Ma J; Wang X
Anticancer Drugs; 2023 Aug; 34(7):803-815. PubMed ID: 36729405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
